Yixintang Pharmaceutical Group Co., Ltd.
Simbol: 002727.SZ
SHZ
18.75
CNYTržna cena danes
23.9311
Razmerje P/E
0.6980
Razmerje PEG
11.17B
Kapaciteta MRK
- 0.02%
Donos DIV
Yixintang Pharmaceutical Group Co., Ltd. (002727-SZ) Finančni izkazi
Bilanca stanja
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 3895.3 | 3520 | 2532.4 | |||||||||||||||
balance-sheet.row.short-term-investments | 0 | 219.7 | 8.4 | 297.3 | |||||||||||||||
balance-sheet.row.net-receivables | 0 | 1991.7 | 2411 | 1777.5 | |||||||||||||||
balance-sheet.row.inventory | 0 | 3852.6 | 3387.4 | 3317 | |||||||||||||||
balance-sheet.row.other-current-assets | 0 | 153.3 | 139.2 | 65.5 | |||||||||||||||
balance-sheet.row.total-current-assets | 0 | 9892.9 | 9457.6 | 7692.4 | |||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 3995.6 | 3993.5 | 4080 | |||||||||||||||
balance-sheet.row.goodwill | 0 | 1649.6 | 1397.2 | 1380 | |||||||||||||||
balance-sheet.row.intangible-assets | 0 | 184.1 | 165.7 | 122.9 | |||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 1833.7 | 1562.9 | 1502.8 | |||||||||||||||
balance-sheet.row.long-term-investments | 0 | 165.3 | 131.4 | -190.1 | |||||||||||||||
balance-sheet.row.tax-assets | 0 | 88.9 | 94.1 | 58.5 | |||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 670.8 | 939.5 | 1193.8 | |||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 6754.5 | 6721.5 | 6645 | |||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-assets | 0 | 16647.4 | 16179.1 | 14337.3 | |||||||||||||||
balance-sheet.row.account-payables | 0 | 2560.2 | 4328.8 | 3805.9 | |||||||||||||||
balance-sheet.row.short-term-debt | 0 | 3333.9 | 1335.5 | 1143.9 | |||||||||||||||
balance-sheet.row.tax-payables | 0 | 81.4 | 250.4 | 164.1 | |||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 1552.2 | 1758.5 | 1764.1 | |||||||||||||||
Deferred Revenue Non Current | 0 | 1.2 | 12.2 | 13.3 | |||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||
balance-sheet.row.other-current-liab | 0 | 1191.9 | 1055.8 | 12.7 | |||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 1557.3 | 1774.7 | 1781 | |||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 1552.2 | 1756.7 | 1729 | |||||||||||||||
balance-sheet.row.total-liab | 0 | 8757.1 | 8651.5 | 7664.8 | |||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.common-stock | 0 | 596 | 596 | 596.2 | |||||||||||||||
balance-sheet.row.retained-earnings | 0 | 4646.4 | 4335.4 | 3504.2 | |||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 377.8 | 424.9 | 405.6 | |||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 2125.8 | 2069.8 | 2071.7 | |||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 7746 | 7426.1 | 6577.7 | |||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 16647.4 | 16179.1 | 14337.3 | |||||||||||||||
balance-sheet.row.minority-interest | 0 | 131 | 101.4 | 94.8 | |||||||||||||||
balance-sheet.row.total-equity | 0 | 7877 | 7527.6 | 6672.5 | |||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||||
Total Investments | 0 | 385 | 139.8 | 107.2 | |||||||||||||||
balance-sheet.row.total-debt | 0 | 4886.1 | 3094 | 2908 | |||||||||||||||
balance-sheet.row.net-debt | 0 | 1210.5 | -417.6 | 672.9 |
Izkaz denarnih tokov
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 549.4 | 1013 | 917.2 | |||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 1000.6 | 1087.8 | |||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | -35.1 | -27.3 | |||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 14.2 | 40.4 | |||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 0 | -9.7 | -603.9 | |||||||||||||||
cash-flows.row.account-receivables | 0 | 0 | -765.8 | -739.7 | |||||||||||||||
cash-flows.row.inventory | 0 | 0 | -234.9 | -1236.8 | |||||||||||||||
cash-flows.row.account-payables | 0 | 0 | 1026.1 | 1399.9 | |||||||||||||||
cash-flows.row.other-working-capital | 0 | 0 | -35.1 | -27.3 | |||||||||||||||
cash-flows.row.other-non-cash-items | 0 | -549.4 | 514.1 | 377.5 | |||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | -349 | -391.6 | |||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | -4.7 | -65.1 | |||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | -980.5 | -1976.5 | |||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 1207.2 | 2901.8 | |||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | -94.7 | -336.9 | |||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 0 | -221.7 | 131.7 | |||||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -207.9 | -137.1 | |||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 2 | 0.1 | |||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | -2 | -0.1 | |||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | -191.6 | -180.9 | |||||||||||||||
cash-flows.row.other-financing-activites | 0 | 0 | -678.6 | -986.8 | |||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 0 | -1078.2 | -1304.8 | |||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0.3 | -0.1 | |||||||||||||||
cash-flows.row.net-change-in-cash | 0 | 0 | 1197.5 | 618.5 | |||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 2859.5 | 2859.5 | 1661.9 | |||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 2859.5 | 1661.9 | 1043.5 | |||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 0 | 2497.1 | 1791.7 | |||||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | -349 | -391.6 | |||||||||||||||
cash-flows.row.free-cash-flow | 0 | 0 | 2148.1 | 1400 |
Vrstica izkaza poslovnega izida
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 17301.4 | 17431.6 | 14587.4 | |||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 11750.3 | 11322.3 | 9196.5 | |||||||||||||||
income-statement-row.row.gross-profit | 0 | 5551 | 6109.3 | 5390.9 | |||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-expenses | 0 | -106.6 | 349.1 | 320.6 | |||||||||||||||
income-statement-row.row.operating-expenses | 0 | 4717.5 | 4496.8 | 4091.3 | |||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 16467.8 | 15819.1 | 13287.8 | |||||||||||||||
income-statement-row.row.interest-income | 0 | -77.6 | 53.4 | 39.2 | |||||||||||||||
income-statement-row.row.interest-expense | 0 | 135.3 | 147.1 | 136.2 | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -123.6 | -426.9 | 28.6 | |||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | -106.6 | 349.1 | 320.6 | |||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -123.6 | -426.9 | 28.6 | |||||||||||||||
income-statement-row.row.interest-expense | 0 | 135.3 | 147.1 | 136.2 | |||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 1332.4 | 1000.6 | 1397.7 | |||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.operating-income | 0 | 833.5 | 1661.9 | 1067.9 | |||||||||||||||
income-statement-row.row.income-before-tax | 0 | 709.9 | 1235 | 1096.5 | |||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 142.2 | 222 | 179.3 | |||||||||||||||
income-statement-row.row.net-income | 0 | 549.4 | 1010 | 921.6 |
Pogosto zastavljeno vprašanje
Kaj je Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) skupna sredstva?
Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) skupna sredstva so 16647375283.000.
Kakšen je letni prihodek podjetja?
Letni prihodki so N/A.
Kolikšna je stopnja dobička podjetja?
Dobiček podjetja je 0.318.
Kakšen je prosti denarni tok podjetja?
Prosti denarni tok je 3.367.
Kolikšna je neto stopnja dobička podjetja?
Čista stopnja dobička je 0.031.
Kolikšni so skupni prihodki podjetja?
Celotni prihodki so 0.045.
Kaj je Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) čisti dobiček (čisti dobiček)?
Čisti dobiček (čisti prihodek) je 549441525.000.
Kolikšen je skupni dolg podjetja?
Skupni dolg je 4886107552.000.
Kolikšni so stroški poslovanja?
Stroški poslovanja so 4717493463.000.
Kolikšno je število denarnih sredstev podjetja?
Denarna sredstva podjetja so 0.000.